Rapport Therapeutics (NASDAQ:RAPP) Stock Rating Lowered by Wall Street Zen

Rapport Therapeutics (NASDAQ:RAPP) was downgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Saturday.

A number of other equities analysts have also weighed in on RAPP. HC Wainwright boosted their price objective on Rapport Therapeutics from $34.00 to $40.00 and gave the stock a “buy” rating in a research note on Tuesday, December 9th. BTIG Research reiterated a “buy” rating and set a $47.00 price target on shares of Rapport Therapeutics in a report on Monday, December 8th. Wells Fargo & Company set a $51.00 price target on shares of Rapport Therapeutics in a research report on Friday, December 19th. Citizens Jmp raised their price objective on shares of Rapport Therapeutics from $77.00 to $80.00 and gave the stock a “market outperform” rating in a research report on Friday, November 7th. Finally, Citigroup reaffirmed a “market outperform” rating on shares of Rapport Therapeutics in a research note on Thursday, January 8th. Seven investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $48.33.

Rapport Therapeutics Trading Down 0.2%

Shares of NASDAQ RAPP opened at $26.81 on Friday. The stock has a market cap of $1.28 billion, a PE ratio of -9.89 and a beta of 1.63. Rapport Therapeutics has a 12-month low of $6.43 and a 12-month high of $42.27. The company has a 50-day moving average of $28.40 and a 200 day moving average of $23.34.

Rapport Therapeutics (NASDAQ:RAPP) last released its earnings results on Thursday, November 6th. The company reported ($0.71) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.77) by $0.06. On average, sell-side analysts forecast that Rapport Therapeutics will post -3.65 EPS for the current fiscal year.

Insider Activity at Rapport Therapeutics

In other Rapport Therapeutics news, CEO Abraham Ceesay sold 5,083 shares of Rapport Therapeutics stock in a transaction dated Wednesday, December 17th. The shares were sold at an average price of $29.63, for a total transaction of $150,609.29. Following the completion of the sale, the chief executive officer directly owned 30,895 shares in the company, valued at $915,418.85. This trade represents a 14.13% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider David Bredt sold 8,500 shares of the business’s stock in a transaction that occurred on Thursday, January 15th. The shares were sold at an average price of $26.84, for a total transaction of $228,140.00. Following the completion of the sale, the insider directly owned 395,575 shares in the company, valued at $10,617,233. This trade represents a 2.10% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 56,739 shares of company stock worth $1,578,630. Company insiders own 13.57% of the company’s stock.

Institutional Trading of Rapport Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Rapport Therapeutics by 86.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,887 shares of the company’s stock valued at $99,000 after purchasing an additional 4,582 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC acquired a new stake in shares of Rapport Therapeutics in the first quarter valued at $2,039,000. Rhumbline Advisers grew its stake in shares of Rapport Therapeutics by 40.1% in the first quarter. Rhumbline Advisers now owns 14,358 shares of the company’s stock valued at $144,000 after buying an additional 4,109 shares in the last quarter. TD Asset Management Inc raised its holdings in shares of Rapport Therapeutics by 20.9% in the 2nd quarter. TD Asset Management Inc now owns 196,870 shares of the company’s stock valued at $2,238,000 after buying an additional 34,052 shares during the period. Finally, Geode Capital Management LLC raised its holdings in shares of Rapport Therapeutics by 5.5% in the 2nd quarter. Geode Capital Management LLC now owns 333,159 shares of the company’s stock valued at $3,789,000 after buying an additional 17,496 shares during the period.

About Rapport Therapeutics

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for patients with cancer. The company leverages a proprietary discovery engine to identify novel tumor-associated antigens and develop tailored biologic and small-molecule candidates designed to modulate key oncogenic pathways. With a pipeline comprising multiple preclinical and early clinical assets, Rapport is committed to advancing precision medicine approaches and addressing unmet needs in oncology.

Rapport’s discovery engine combines high-throughput screening, molecular profiling and in vivo validation to accelerate the progression of lead candidates from the laboratory to clinical evaluation.